大鼠脑肿瘤模型中钆吡醇与钆特酸、钆贝酸和钆布醇的对比剂-剂量关系比较
本研究在大鼠C6胶质瘤模型中比较了新型大环状钆对比剂钆吡醇与三种常规钆对比剂的MRI增强效果。结果显示钆吡醇在0.025至0.1 mmol/kg范围内对比噪声比变化呈线性剂量依赖(R²=0.99),0.05 mmol/kg钆吡醇与0.1 mmol/kg常规对比剂相比获得相似的对比噪声比变化和形态学表征。
要点
- 钆吡醇0.05 mmol/kg与常规对比剂0.1 mmol/kg的肿瘤对比噪声比变化和形态学评分相当。
- 钆吡醇0.1 mmol/kg的对比噪声比变化是常规对比剂的两倍。
- 钆吡醇在0.025至0.1 mmol/kg范围内对比噪声比变化呈线性剂量依赖(R²=0.99)。
核心结论
- 钆吡醇0.05 mmol/kg与钆贝酸、钆特酸或钆布醇0.1 mmol/kg相比,产生相似的对比噪声比变化和脑肿瘤形态学表征。
研究设计与样本
- 2012年4月至7月间,32只植入C6胶质瘤的大鼠接受两次静脉注射,间隔24小时,注射药物随机选自五种剂量的钆吡醇(0.025、0.05、0.075、0.1和0.2 mmol/kg)和三种参考对比剂(钆特酸葡甲胺、钆布醇和钆贝酸二甲葡胺)0.1 mmol/kg。
关键影像表现/征象
- 在T1加权图像上评估注射前至注射后30分钟内的肿瘤强化。
- 两名盲法放射科医师对对比增强、边界勾画和肿瘤形态可视化进行视觉定性评分。
- 定量计算各时间点肿瘤与对侧实质之间的对比噪声比变化(ΔCNR),并在5分钟时采用混合模型比较各处理组。
诊断标准与关键数值
- 钆吡醇在0.025至0.1 mmol/kg范围内ΔCNR呈线性剂量依赖关系(R²=0.99)。
- 三种参考对比剂之间ΔCNR无差异(P ≥ .55)。
- 钆吡醇0.1 mmol/kg的ΔCNR为两倍高(与钆布醇和钆特酸比较P < .001,与钆贝酸比较P = .002)。
- 钆吡醇0.05 mmol/kg的ΔCNR相似(与钆布醇比较P = .56,与钆贝酸比较P > .99,与钆特酸比较P = .44)。
- 两名阅读者评分:钆吡醇0.05 mmol/kg改善对比增强、边界勾画和肿瘤形态可视化(评分> 3,而市售对比剂评分为2至3)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Detection of cerebral lesions at MRI may benefit from a chemically stable and more sensitively detected gadolinium-based contrast agent (GBCA). Gadopiclenol, a macrocyclic GBCA with at least twofold higher relaxivity, is currently undergoing clinical trials in humans. Purpose To determine the relationship between MRI contrast enhancement and the injected dose of gadopiclenol in a glioma rat model compared with those of conventional GBCA at label dose. Materials and Methods Between April and July 2012, 32 rats implanted with C6 glioma received two intravenous injections at a 24-hour interval. The injections were randomly selected among five doses of gadopiclenol (0.025, 0.05, 0.075, 0.1, and 0.2 mmol/kg) and three reference GBCAs (gadoterate meglumine, gadobutrol, and gadobenate dimeglumine) at 0.1 mmol/kg. MRI tumor enhancement was assessed on T1-weighted images before and up to 30 minutes after injection. Two blinded radiologists visually and qualitatively scored contrast enhancement, border delineation, and visualization of tumor morphology. Quantitatively, variations in contrast-to-noise ratio (ΔCNR) between tumor and contralateral parenchyma were calculated at each time point and were compared for each treatment at 5 minutes by using a mixed model after normality test. Results A total of 24 rats underwent the complete protocol (n = 5-7 per group). A linear dose-dependent ΔCNR relationship was observed between 0.025 and 0.1 mmol/kg for gadopiclenol (R 2 = 0.99). No difference in ΔCNR was observed between the three reference GBCAs (P ≥ .55). Gadopiclenol resulted in twofold higher ΔCNR at 0.1 mmol/kg (P < .001 vs gadobutrol and gadoterate, P = .002 vs gadobenate) and similar ΔCNR at 0.05 mmol/kg (P = .56, P > .99, and P = .44 compared with gadobutrol, gadobenate, and gadoterate, respectively). For both readers, 0.05 mmol/kg of gadopiclenol improved contrast enhancement, border delineation, and visualization of tumor morphology (scores > 3 compared with scores between 2 and 3 for the marketed GBCA). Conclusion Gadopiclenol at 0.05 mmol/kg yielded comparable change in contrast-to-noise ratio and morphologic characterization of brain tumors compared with gadobenate, gadoterate, or gadobutrol at 0.1 mmol/kg. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Tweedle in this issue.
引用
- Robert P, Vives V, Grindel AL, et al. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model. Radiology. 2019. PMID: 31660804. doi:10.1148/radiol.2019182953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。